Mitochondrial diseases are clinically and genetically heterogeneous, with variable penetrance, expressivity, and differing age of onset. Diseasecausing point mutations and large deletions in the mitochondrial genome often exist in a heteroplasmic state. Current molecular analyses require multiple different and complementary methods for the detection and quantification of mitochondrial DNA (mtDNA) mutations. We developed a novel approach to analyze the mtDNA in 1 step.
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One in 200 healthy individuals is at risk for developing mitochondrial disease due to mitochondrial DNA (mtDNA) 2 mutations (1 ). Mitochondrial disorders are clinically and genetically heterogeneous, with variable penetrance, expressivity, and differing age of onset (2, 3 ) . Deleterious mtDNA mutations are usually present in a heteroplasmic state (4 ) . The type of mtDNA mutation, the tissue distribution of the mtDNA mutation, and its degree of heteroplasmy contribute to the clinical phenotype and severity of the disease. A female carrying a pathogenic mtDNA mutation is at risk of passing the mutation to her offspring, even if she is asymptomatic with low-level heteroplasmy in somatic cells. In addition, there is growing evidence that somatic mtDNA alterations are associated with aging and a variety of common diseases, including diabetes and cancers (5) (6) (7) (8) (9) (10) .
Current molecular diagnostic methods for the detection and quantification of mtDNA mutations are based on the screening of a panel of common point mutations followed by the quantification of the mutant load. If the screening results are negative, sequencing of the whole mitochondrial genome is performed to find causative rare variants or novel mutations. Although the gold standard, Sanger sequencing, reliably detects most nucleotide changes, it does not provide quantitative information and is not adequately sensitive for detecting mutant heteroplasmy below 15% (11 ) . Large mtDNA deletions are analyzed separately by Southern blotting (12 ) or by custom-designed array comparative genome hybridization (aCGH) (13, 14 ) . Nevertheless, neither method by itself can provide deletion breakpoints and heteroplasmy. In addition, quantification of the degree of heteroplasmy at any given nucleotide position is limited. Thus, there is an urgent need for an accurate, comprehensive and costeffective method for the molecular diagnosis of mtDNA-based diseases.
Here, we report a one-step approach that uses massively parallel sequencing (MPS) to provide quantitative base calls, exact deletion junction sequences, and quantification of deletion heteroplasmy. To adapt this method for molecular diagnosis in a clinical setting, necessary qualitative and quantitative controls were developed for inclusion in the analysis of each indexed sample for quality assurance.
Materials and Methods

PATIENTS AND DNA EXTRACTION
Patients were referred to the Mitochondrial Diagnostic Laboratory at the Medical Genetics Laboratories of Baylor College of Medicine for the mutational evaluation of mitochondrial disorders. Total DNA was isolated from either peripheral blood lymphocytes or muscle biopsy performed with a commercially available DNA isolation kit (Gentra) according to the manufacturer's protocols. The analyses were performed according to the institutional review board-approved protocols for human study participants at the Baylor College of Medicine.
SELECTION OF DNA SAMPLES FOR MPS ANALYSIS
Seventeen samples with known deleterious point mutations identified by Sanger or ASO (allele-specific oligonucleotide) dot blot screening (15 ) and quantified by amplification refractory mutation system (ARMS) quantitative PCR (qPCR) (16 ) were selected. The entire mitochondrial genome was amplified by using 24 pairs of sequence-specific overlapping primers (17) (18) (19) . GenBank sequence NC_012920.1 was used as a reference. Twenty-six samples with or without known deleterious mutations identified by Sanger sequencing were also analyzed by this method. Common point mutations were quantified by use of ARMS qPCR according to published protocols (16, 20 ) . Large mtDNA deletions were detected by Southern blot or aCGH and deletion breakpoints and heteroplasmy was determined accordingly (13 ) .
LONG-RANGE PCR
The forward and reverse primers were: mt16426F (5Ј-CCGCACAAGAGTGCTACTCTCCTC-3Ј) and mt16425R (5Ј-GATATTGATTTCACGGAGGATGGTG-3Ј). We performed PCR using a TaKaRa LA Taq Hot Start polymerase kit (TaKaRa) and 100 ng of total genome DNA isolated from blood or 15 ng from skeleton muscle as template in a 50-L PCR system. An initial 2-min incubation at 95°C was followed by 30 cycles of PCR with 20 s of denaturation at 95°C and 18 min of annealing and extension at 68°C. The reaction was completed by 1 cycle of final extension at 68°C for 20 min; 1.5-L PCR product was analyzed on 1.5% agarose gel with 1 kb plus DNA ladder (Invitrogen).
MULTIPLEX PCR OF 14 NUCLEAR MARKER REGIONS FOR
INTERNAL QCs
Internal QC (InQC) primers (see Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol58/ issue9) were designed to amplify 14 different nuclear gene loci. We performed PCR with Roche FastStart Taq DNA polymerase (Roche Diagnostics) using 7.5 ng of total genomic DNA template in a 50-L PCR system.
PCR FOR EXTERNAL QCs AND DEEP SEQUENCING INDEX
External QCs (ExQCs) were 7 synthetic DNA fragments, each 150 bp long with known variants at specific positions. We cloned these DNA fragments into an EcoRV-digested pBluescriptII SK(Ϫ) vector and used FastStart Taq DNA polymerase to amplify them with a primer pair (forward primer, 5Ј-GAGAGTAATCT GTGCTCTGGC-3Ј; reverse primer, 5Ј-ACCGTTA GCGTGGCAG-3Ј). The diluted PCR products were pooled together according to the volumes listed in online Supplemental Table 2 to make 1 mL ExQC solution containing 0.1%, 0.5%, 2%, 5%, 20%, and 50% of wild type and variants 1, 2, 3, 4, 5, and 6, respectively. The 80% and 100% was determined from the major allele of 20% and 0%.
A deep-sequencing index (DSI) formula was developed to evaluate the performance of each sequencing run and to compare the quality of sequencing results among different gene enrichment methods (Fig.  4A ). This equation contained 6 parameters, with each having an empirically assigned weight. The 6 parameters were (a) the mean number of reads mapped to ExQC DNA, (b) the mean number of sample reads normalized to the mean number of reads of ExQC DNA, (c) the correlation coefficient of the expected vs observed values of ExQC DNA heteroplasmy, (d) the ratio of the SD of the mean number of reads to the mean number of reads mapped to sample DNA, (e) the analytic specificity, and (f) the analytic sensitivity of a run determined from the reads mapped to mtDNA. The analytic specificity of a run was defined as the percentage of reads mapped to an mtDNA reference sequence compared to total reads generated for the sample, which, for the capture-based enrichment was approximately 20% and for the LR-PCR based was approximately 99%. The analytic sensitivity of a run was defined as the percentage of bases of the reference sequence covered by MPS reads.
DNA TEMPLATE LIBRARY PREPARATION FOR ILLUMINA
INDEXED SEQUENCING
Indexed paired-end DNA libraries were prepared according to the manufacturer instructions with minor modifications. Briefly, LR-PCR products were fragmented to 200 bp, which were purified with AMPure XP beads. After end repair, 3Ј-adenylation, and Illumina InPE adapter ligation, DNA samples were enriched by PCR with Herculase II polymerase (Agilent Technologies). Twelve indexed DNA libraries were pooled together with equal molar ratios. Each pooled library was sequenced in a single lane of 1 flow cell on HiSeq2000 with a 76-or 100-bp paired-end or singleend read chemistry.
DATA FILTERING AND ANALYSIS
After demultiplexing with Illumina CASAVA software the reads belonging to the same index were filtered to remove any reads with median quality score below 25 by NextGENe software (SoftGenetics). Reads with 1 unknown assigned base call were also removed. The data were processed and variant calls were made with 2 different heteroplasmy cutoff values, 20% and 1%. The aligned reads were examined with a NextGENe Viewer. The degree of deletion heteroplasmy was calculated on the basis of the segmental mean read depth of the deleted and undeleted regions.
Results
DEEP COVERAGE ALLOWS ACCURATE QUANTITATIVE BASE CALLS
To examine each nucleotide of the entire 16.6 kb mitochondrial genome, a long-range PCR (LR-PCR) with a set of nonoverlapping back-to-back primers was used to amplify the entire mitochondrial genome, providing uniform coverage and sufficient depth for the quantification of heteroplasmy. All variant calls made by Sanger sequencing were confirmed by the MPS method. In addition, the MPS data provided quantitative information for the level of heteroplasmy. An m.1630AϾG (tRNA Val) variant was detected by MPS at a 3.7% heteroplasmy, but was not detected by Sanger sequencing (Table 1A ; also see online Supplemental Fig. 1 ) in the asymptomatic mother of a 2-year old affected child who harbored 33% heteroplasmy for the same variant. Studies of matrilineal family members and clinical correlation revealed that the m.1630AϾG cosegregated with the disease and was likely to be a causative mutation. The detection of heteroplasmy of the m.1630AϾG mutation in the mother also indicated that the recurrence risk in her case was higher than that for a simplex case. Table 1B shows the results of base calls for 26 samples analyzed by MPS compared to those of Sanger sequencing. Both methods identified concordant nucleotide changes with the exception of these heteroplasmic calls: the low heteroplasmy m.1630AϾG described above, an m.16193insC variant present at 15.2% heteroplasmy detected by MPS but missed by Sanger sequencing, and a high heteroplasmy of m.303insC/CC identified by MPS but identified as homoplasmic by Sanger sequencing (see online Supplemental Fig. 2 ). Small insertions and deletions within a homopolymeric stretch, such as m.303_309insC, m.311_315insC, and m.16193insC, were also accurately identified by MPS.
DETECTION OF mtDNA LARGE DELETION, ITS BREAKPOINT AND HETEROPLASMY
One advantage of amplification of the entire mitochondrial genome by LR-PCR performed with a single pair of primers is to provide uniform coverage and allow for easy detection of large deletions (Fig. 1A) . Large mtDNA deletions with deletion breakpoints are clearly shown. The degree of deletion heteroplasmy can be calculated from the ratio of the mean coverage at the deleted region to the mean coverage at the nondeleted region. Several samples with known mtDNA deletions were analyzed by LR-PCR followed by deep sequencing (Fig. 1B) . The results of deletion junctions, size of deletion, and degree of heteroplasmy detected by MPS were consistent with the results obtained from target aCGH/Southern blotting (13, 21 ) (Fig. 1C) . Notably, we observed enhanced analytic sensitivity for detecting large mtDNA deletions by MPS, likely due to the preferential amplification of the shorter fragments.
QUANTIFICATION OF HETEROPLASMIC POINT MUTATIONS BY MPS
The other advantage of deep sequencing is that it enables the accurate quantification of the heteroplasmy of each nucleotide. Samples with known heteroplasmic mutations m.3243AϾG, m.8993TϾC, m.11778GϾA, m.14484TϾC, m. 13513GϾA, and m.10191TϾC were evaluated by deep sequencing. Table 2 shows different percentages of heteroplasmic point mutations determined by MPS across the mtDNA genome. In general, the results from MPS were in good agreement with those obtained by using the ARMS qPCR method. The deviations between the 2 methods are likely attributable to the intrinsic differences in the design of the methods. Because of the presence of a large amount of mtDNA sequences in the nuclear chromosomes (called NUMTs, see Discussion), we believe the MPS method to be more accurate than the ARMS qPCR method for reflecting the true mtDNA heteroplasmic status. 
ASSESSMENT OF ANALYTIC ERROR, LIMIT OF DETECTION, AND
REPRODUCIBILITY
To assure that the quantification of heteroplasmy by MPS was reliable, a set of cloned synthetic 150-bp control DNAs was supplemented into each indexed sample as ExQCs. To mimic a range of heteroplasmy, different proportions of control DNAs with different nucleotide changes at specific positions were mixed to form a se- Table 3 .
ries of mixtures. To evaluate the reliability of quantitative measurements, the spiked control DNA was indexed together with each sample by using the same bar code during library preparation. The control DNA sequences, except the nucleotide positions marked for heteroplasmy measurements, were used to calculate error rates. The instrumental sequencing error was determined by the number of incorrect nucleotides of the control DNA sequences vs the total number of nucleotides mapped to the control DNA sequences. The sample DNA had an analytic error rate of 0.326% Ϯ 0.335% compared to 0.151% Ϯ 0.394% for the control DNAs (Fig. 2A) . Thus, the limit of detection, calculated as 3 SDs above the mean error (0.326 ϩ 3 ϫ 0.335), was 1.33% under our current experimental, instrumental, and analytic conditions (22, 23 ) . It is worth noting that the experimental procedures can introduce errors, which, in general, are higher for mtDNA samples than for the ExQC control, as shown in Fig. 2A . However, errors could be high for some control DNAs, which reflected higher error rates in samples 4, 5, and 6 ( Fig. 2A) . The observed and the expected percentages of the variants at specific positions exhibited an excellent correlation (Fig. 2B) .
To measure the reproducibility of this method for heteroplasmy detection, an admixed sample of mitochondrial haplogroups H and J (Fig. 3) were analyzed in 2 independent Illumina runs. The percentage heteroplasmy in these 2 runs was in excellent agreement; the Pearson's correlation coefficient for the 2 runs was 0.998, with a P value Ͻ0.001 (Fig. 3) .
PERFORMANCE EVALUATION BY DEEP DSI
With the use of the DSI, the quality of MPS performance among 3 different gene enrichment methods was evaluated. Fig. 4B represents the result of gene enrichment performed with SureSelect solution-based capture with RNA probes, showing an uneven coverage from as low as 1000ϫ to as high as 50 000ϫ throughout the mtDNA genome. By mixing 24 overlapping PCR products of the mtDNA followed by deep sequencing, the coverage is uniform within each PCR fragment itself but varies from roughly 5000ϫ to 40 000ϫ among different PCR fragments, with overlapping regions covered excessively at Ͼ80 000ϫ (Fig. 4C) . In contrast, Fig. 4D shows the uniform coverage throughout the entire mitochondrial genome when the mtDNA genome was enriched by a single LR-PCR amplification. Assuming that each of the 6 parameters is given the weight of 1, 2, 2, Ϫ3, 1, and 5, respectively, the DSI, for SureSelect capture-based, 24 overlapping PCR fragments, and LR-PCR gene enrichment methods was calculated to be about 36, 74, and 90, respectively.
SAFEGUARD OF INDEXED SAMPLES
For a diagnostic laboratory, one very important factor is the cost of the test. Because of the high throughput of the MPS instruments as well as the high reagent cost of a run, it is often desirable to pool samples from different individuals together to be analyzed in a single lane. When tens to hundreds of samples are pooled and sequenced simultaneously, the cost for analysis is greatly reduced, but the likelihood of a sample mix-up is also increased. Ensuring that every indexed sample is scored correctly is very important for a diagnostic laboratory; thus, an internal identity control system (InQC) was designed and incorporated into the analysis of each sample.
Fourteen nuclear DNA regions containing polymorphic markers were amplified in a multiplex PCR reaction, and the resulting DNA fragments were mixed with the LR-PCR-enriched mtDNA fragments from the same individual for indexing and MPS. In parallel, genotyping the same 14 nuclear markers of the same sample by either TaqMan assay or Sanger sequencing was performed independently. Primer sets used in the production of InQC are listed in online Supplemental Table 1 . The genotyping result derived from the parallel testing was compared to those generated by MPS to verify sample identity. An unmatched result is always an indication of sample switching or crosscontamination during procedures such as the library preparation process. Should these results not match, repeat analysis or other investigation is warranted. This InQC system is absolutely required in a clinical diagnostic setting, particularly when patient samples are mixed for analyses performed with complex procedures.
Discussion
ADVANTAGES OF LR-PCR OF THE ENTIRE MITOCHONDRIAL
GENOME
Approximately 650 distinctive regions in the human genome have Ͼ60% sequence similarity to mtDNA, as documented in the MITOMAP database (www. mitomap.org/bin/view.pl/MITOMAP/PseudogeneList). The mean sequence similarity in these regions is 80% Ϯ 7.4%, and the mean length of homologous fragments is 944 bp Ϯ 1569 bp (24 ) . During data analysis, it is difficult to filter those nuclear gene sequences that are nearly identical to mtDNA, such as the 9p24.3, 12q11, and Yp11.3 regions. The pooling of 24 PCR-fragments-based target gene enrichment can efficiently cover the entire mtDNA genome with overlapping PCR fragments. However, because of the highly polymorphic nature of the mtDNA, the use of multiple primer sets increases the chance of having a rare or novel variant at the primer binding sites, resulting in differential PCR efficiency among different amplicons and making the detection of large deletions almost impossible. These problems can be solved by using 1 pair of primers directed at a conserved region near the mtDNA origin of replication.
DEEP COVERAGE ALLOWS ACCURATE BASE CALLS AND THE
LIMIT OF DETECTION OF mtDNA HETEROPLASMY
For the identification of mutations in nuclear genes, a coverage of Ͼ30ϫ sequence reads would usually be considered adequate for making homozygous or heterozygous base calls, and the detection of small indel variations for research purposes (25, 26 ) . Previous studies in which MPS was used to quantify mtDNA heteroplasmy were carried out with either multiple overlapping amplicons covering the entire mtDNA or a single amplicon targeting a small selected region of interest (27) (28) (29) (30) . It has been shown that the analytic sensitivity of heteroplasmy detection is correlated with the coverage depth (30 ) . We routinely had a coverage depth at about 10 000 -20 000-fold for the mitochondrial genome (Fig. 2) .
Sanger sequencing analysis generally cannot detect heteroplasmy below approximately 15% (11 ) . The deep coverage allows the detection of very low mutation heteroplasmy at any of the 16 569 nucleotide positions, with a limit of detection at about 1.33% based on 3 SDs above the mean error (Fig. 2) . This approach is very stringent, with 99.9% confidence. In fact, a sample with 1.1% heteroplasmy has been routinely included as a positive control and it has been detected in every single run. The 1.1% heteroplasmy is 2 SDs above the mean error and can be detected with 95% confidence. However, the error rate in the control DNAs can be as high as 1.5%-2% (Fig. 3A) , which may result in false-positive calls. To balance between the falsepositive and false-negative calls, we chose to use the more stringent cutoff of 1.33%. For every positive variant scored, sequence specific errors (31 ) including sequences in the homopolymer tracts or repeat regions, and at the beginning or the end of a sequence read, or a high rate of miscall due to a particular secondary structure, are ruled out, followed by confirmation of the positive calls with a repeat analysis or by a second method to verify the variant. In addition, when a low heteroplasmy of a known mutation is detected below the limit of detection, it is also confirmed by repeat analysis.
The deep sequencing method has been successfully adapted to study somatic mtDNA alterations in various tissues, such as muscle, blood, or tumor samples. Somatic mtDNA alterations have been reported in many types of cancers and may play a role in tumorigenesis (5, (32) (33) (34) (35) . However, relatively few cancers harbor detectable deleterious somatic mtDNA mutations (6, 36, 37 ) . This hypothesis may be tested by using the deep sequencing approach which, in theory, reaches a level of detection equivalent to singlemolecule analysis.
HETEROPLASMY QUANTIFICATION WITH DIFFERENT
METHODOLOGIES
As listed in Table 2 , discrepancies in the degree of heteroplasmy measured by ARMS qPCR and MPS were observed, although most of them were consistent. This inconsistency was most likely due to the fundamental differences in these methodologies. ARMS qPCR is based on the discrimination of the 3Ј end nucleotide of either the forward or the reverse primer for the extension of DNA synthesis (16 ) . The reported percentage of heteroplasmy may be influenced by the efficiency of PCR due to different primers. However, for MPS, the same primer set was used in LR-PCR between the wildtype and mutant mtDNA molecules. The discrepancy between these 2 methods may also be due to the presence of nuclear mitochondrial DNA, which is not amplified by LR-PCR.
The percentage of mtDNA deletion heteroplasmy calculated from the LR-PCR/MPS method was also not in perfect agreement with that estimated from array CGH (13 ) (see online Supplemental Table 3 ). This result was likely due to the preferential amplification of smaller molecules resulting in an overestimation of deletion molecules, translating into a higher apparent heteroplasmy of mtDNA deletion. With deep coverage, examination of the breakpoints sequence should allow the detection of complex mtDNA rearrangements, including multiples deletion and partial duplication.
QCs ARE ESSENTIAL IN PERFORMANCE EVALUATION
To evaluate the instrumental and experimental errors and to determine the limit of detection, DNA fragments with known sequences in various ratios were added to and indexed with each sample as a QC measure, and processed exactly as the test sample. This approach helps in identifying the sources of any errors and setting the guidelines for the secondary analysis of the clinical samples, including mapping the reads, base calling, and calculation of heteroplasmy. The inclusion of QCs in clinical samples is especially important for assuring the quality of performance and determining the limit of detection for quantitative measurements of heteroplasmy.
UTILITY OF THE DSI
Various platforms and target gene enrichment methods have been used in different clinical diagnostic laboratories for MPS. Data quality may vary among laboratories and currently there is no standard guideline for performance comparison. It is thus important to develop a uniform approach to assess the performance of high throughput MPS among various laboratories. Such an approach will provide standardized evaluations to compare interlaboratory results and intralaboratory assessments, and to assure quality performance.
In summary, our results demonstrated that LR-PCR of the whole mitochondrial genome followed by deep sequencing may be considered as the new standard for the analysis of the mitochondrial genome. This one-step comprehensive approach makes qualitative and quantitative calls for every nucleotide position of the entire mitochondrial genome. It can simultaneously detect large mtDNA deletions as well as small indels, identifying both the breakpoints and the degree of heteroplasmy. We believe this novel approach will greatly facilitate the diagnosis of mitochondrial diseases in a timely and cost-effective fashion.
